TGFBI and corneal dystrophy: In the cornea, ex vivo studies have shown that CRISPR/Cas9 can precisely correct pathogenic TGFBI mutations in patient-derived keratocytes, supporting the concept of mutation-specific gene editing for monogenic corneal dystrophies [99].